Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

PHASE3TerminatedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

April 24, 2020

Study Completion Date

May 9, 2020

Conditions
Primary HypercholesterolemiaMixed Dyslipidemia
Interventions
DRUG

evolocumab

Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.

DRUG

placebo

Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.

Trial Locations (31)

100191

Peking University Third Hospital, Beijing

100730

Beijing Hospital, Beijing

110016

The Peoples Hospital of Liaoning Province, Shenyang

130033

China-Japan Union Hospital of Jilin University, Changchun

150001

The First Affiliated Hospital of Harbin Medical University, Harbin

200040

Huashan Hospital Affiliated to Fudan University, Shanghai

200090

Shanghai Yangpu District Central Hospital, Shanghai

212001

Affiliated Hospital of Jiangsu University, Zhenjiang

215000

Suzhou Kowloon Hospital, Suzhou

221006

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

250013

Jinan Central Hospital, Jinan

300052

Tianjin Medical University General Hospital, Tianjin

300140

Tianjin Fourth Centre Hospital, Tianjin

310013

Zhejiang Hospital, Hangzhou

315010

Ningbo First Hospital, Ningbo

317000

Taizhou Hospital of Zhejiang Province, Linhai

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

330006

The Second Affiliated Hospital to Nanchang University, Nanchang

410004

Changsha Central Hospital, Changsha

410008

Xiangya Hospital Central South University, Changsha

410011

The Second Xiangya Hospital of Central South University, Changsha

410013

The Third Xiangya Hospital of Central South University, Changsha

430030

Wuhan Puai Hospital, Wuhan

510080

Guangdong Provincial Peoples Hospital, Guangzhou

510120

Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou

510180

Guangzhou First Peoples  Hospital, Guangzhou

510220

Guangzhou Red Cross Hospital, Guangzhou

518036

Peking University Shenzhen Hospital, Shenzhen

530031

The Second Nanning Peoples Hospital, Nanning

710061

The First Affiliated Hospital of Xi An Jiao Tong University, Xi’an

010017

Inner Mongolia Peoples Hospital, Hohhot

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY